medigraphic.com
ISSN 1561-2937 (Print)

2021, Number 4

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2021; 27 (4)

Cardiovascular risk factors, diabetes and COVID-19

Campos VNA, Real CRM, Rivas EE

Language: Spanish
References: 24
Page: 2-6
PDF size: 290.35 Kb.


ABSTRACT

People with cardiovascular disease (CVD) are at increased risk of developing severe COVID-19 and dying from it. According to the WHO, the mortality rate in patients with SARS-CoV-2 / COVID-19 with pre-existing cardiovascular disease is 10.5%, with arterial hypertension (HT) it is 6% and without pre-existing conditions is 0.9%. This estimate appears to be lower than that seen with other viral infections. Recent publications have shown that its relationship with COVID-19 can lead to a worsening of insulin resistance, especially in obese patients and can even induce an inflammatory process, due to an inappropriate response and exaggerated production of IL-6, IL-1. All this is reflected in an increase in hospitalizations and a worse prognosis in these patients. Which highlights the importance of promoting self-care and social education about this pathology.


REFERENCES

  1. Figueroa Triana JF, Salas Márquez DA, Cabrera Silva JS, Alvarado Castro CC, Buitrago Sandoval AF. COVID-19 y enfermedad cardiovascular. Rev Colomb Cardiol [Internet]. 17 de abril de 2020 [citado 31 de julio de 2020]; Disponible en: http://www.sciencedirect.com/science/article/pii/S0120563320300760

  2. Covid-19 y el Riesgo de Olvidarnos de la Enfermedad Cardiovascular... [Internet]. Cardiología Hoy. 2020 [citado 31 de julio de 2020]. Disponible en: https://cardiologiahoy.com/2020/03/31/covid-19-y-el-riesgo-de-olvidarnos-de-la-enfermedad-cardiovascular/

  3. OPS. HIPERTENSIÓN Y ENFERMEDADES CARDIOVASCULARES DURANTE LA PANDEMIA DE COVID-19 _spa.pdf (2020) [Internet]. [citado 31 de julio de 2020]. Disponible en: https://iris.paho.org/bitstream/handle/10665.2/52383/OPSNMHNVCOVID-19200020_spa.pdf?sequence=1&isAllowed=y

  4. CONCENSO INTERINO DE CARDIOLOGIA INFORMADO EN LA EVIDENCIA SOBRE COMPLICACIONES CARDIOVASCULARES DE SARS-COV-2/COVID-19 .(2020):22 https://www.salud.gob.ec/consenso-multidisciplinario-informado-en-la-evidencia-sobre-el-tratamiento-de-covid-19/

  5. Clerkin, Kevin J., et al. "Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease." Circulation 2020. doi.org/10.1161/CIRCULATIONAHA.120.046941

  6. Mehra, Mandeep R., et al. "Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19." New England Journal of Medicine. 2020. DOI: 10.1056/NEJMoa2007621

  7. Hanna TP. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol [Internet]. 2020; Available from: http://dx.doi.org/10.1038/s41571- 020-0362-6

  8. Zhang H, Penninger JM, Li Y, Zhong N and Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. March 3, 2020. doi: 10.1007/s00134-020-05985-9

  9. Zheng, Ying-Ying, et al. "COVID-19 and the cardiovascular system." Nature Reviews Cardiology 2020: 1-2.

  10. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of coronavirus disease 2019 in China [published online ahead of print, 2020 Feb 28]. N Engl J Med. 2020;10.1056/NEJMoa2002032. doi:10.1056/NEJMoa2002032

  11. Wu Z and McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020. doi: 10.1001/jama.2020.2648.

  12. Wang, Dawei, et al. "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China." JAMA.2020; 323, ( 11): 1061.1069

  13. Bavishi, Chirag, Thomas M. Maddox, and Franz H. Messerli. "Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers." JAMA cardiology. 2020. doi:10.1001/jamacardio.2020.1282

  14. Salazar M, Barochiner J, Espeche W, Ennis I. COVID-19, hipertensión y enfermedad cardiovascular. Hipertens Riesgo Vasc. junio de 2020;S1889183720300659.

  15. Qingxian, Cai, et al. "Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China." China, Qingxian, Cai and Fengjuan, Chen and Fang, Luo and Xiaohui, Liu and Tao, Wang and Qikai, Wu and Qing, He and Zhaoqin, Wang and Yingxia, Liu and Jun, Chen and Lei, Liu and Lin, Xu, Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China (3/13/2020). Available at SSRN: https://ssrn.com/abstract=3556658 or http://dx.doi.org/10.2139/ssrn.3556658

  16. Vardavas, Constantine I., and Katerina Nikitara. "COVID-19 and smoking: A systematic review of the evidence." Tobacco induced diseases 18, 2020. doi: 10.18332/tid/119324

  17. LI, Bo, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology, 2020: 1-8.

  18. Bavishi, Chirag, Thomas M. Maddox, and Franz H. Messerli. "Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers." JAMA cardiology. 2020. doi:10.1001/jamacardio.2020.1282

  19. Saldarriaga-Giraldo, C., Navas, V., & Morales, C. (2020). De la diabetes a la insuficiencia cardiaca ¿Existe la miocardiopatía diabética? Revista Colombiana de Cardiología, 27, 12–16.

  20. Bellido V, Pérez A. Consequences of COVID-19 on people with diabetes. Endocrinol Diabetes y Nutr [Internet]. 2020 Jun 1 [cited 2020 Jul 5];67(6):355–6. Available from: www.elsevier.es/endo.

  21. Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes Metab Syndr Clin Res Rev [Internet]. 2020 Jul 1 [cited 2020 Jul 5];14(4):513–7. Available from: https://doi.org/10.1016/j.dsx.2020.04.049.

  22. Iacobellis G. COVID-19 and diabetes: Can DPP4 inhibition play a role? Vol. 162, Diabetes Research and Clinical Practice. Elsevier Ireland Ltd; 2020.

  23. Bode, B., Garrett, V., Messler, J., McFarland, R., Crowe, J., Booth, R., & Klonoff, D. C. (2020). Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. Journal of Diabetes Science and Technology, 1932296820924469.

  24. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diab Res Care [Internet]. 2020 [cited 2020 Jul 5];8:1343. Available from: http://drc.bmj.com/




2020     |     www.medigraphic.com